VABOMERE is a Intravenous Injection, Powder, For Solution in the Human Prescription Drug category. It is labeled and distributed by The Medicines Company. The primary component is Vaborbactam; Meropenem.
| Product ID | 65293-009_580db23f-c656-3049-e053-2a91aa0ad616 |
| NDC | 65293-009 |
| Product Type | Human Prescription Drug |
| Proprietary Name | VABOMERE |
| Generic Name | Meropenem-vaborbactam |
| Dosage Form | Injection, Powder, For Solution |
| Route of Administration | INTRAVENOUS |
| Marketing Start Date | 2017-10-02 |
| Marketing Category | NDA / NDA |
| Application Number | NDA209776 |
| Labeler Name | The Medicines Company |
| Substance Name | VABORBACTAM; MEROPENEM |
| Active Ingredient Strength | 1 g/2g; g/2g |
| Pharm Classes | beta Lactamase Inhibitor [EPC],beta Lactamase Inhibitors [MoA],Carbapenems [CS],Penem Antibacterial [EPC] |
| NDC Exclude Flag | E |
| Listing Certified Through | 2018-12-31 |
| Marketing Start Date | 2017-10-02 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA209776 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2017-10-02 |
| Marketing End Date | 2019-07-31 |
| Marketing Category | NDA |
| Application Number | NDA209776 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2017-10-02 |
| Marketing End Date | 2019-07-31 |
| Inactivation Date | 2020-01-31 |
| Reactivation Date | 2020-02-12 |
| Ingredient | Strength |
|---|---|
| VABORBACTAM | 1 g/2g |
| SPL SET ID: | 580db23f-c655-3049-e053-2a91aa0ad616 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 65293-009 | VABOMERE | Meropenem-Vaborbactam |
| 70842-120 | VABOMERE | Meropenem-Vaborbactam |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() VABOMERE 87394992 5566623 Live/Registered |
The Medicines Company 2017-03-31 |